Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Doxorubicin and Gemcitabine vs FOLFOX4 in Advanced HCC
NCT02527772Phase 3Withdrawn
- Sponsor
- Guangxi Medical University
- Start
- Sep 2015
- Primary completion
- Sep 2017
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin, gemcitabine in hepatocellular carcinoma (HCC), sponsored by Guangxi Medical University. Planned start Sep 2015; status: withdrawn.
02
Drugs
pegylated liposomal doxorubicingemcitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02527772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02527772.